Showing results (201-210 of 234) with videos related to
Sort By:
Pageof 24
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 18, 2016
Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and ThiotepaBarbara Spitzer, Miguel-Angel Perales, Nancy A Kernan, et al.Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.Journal of Comparative Effectiveness Research|April 28, 2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myelomaAmrita Krishnan, Ajay K Nooka, Ajai Chari, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.Targeted Oncology|March 26, 2026
Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine DynamicsNatalia A Quijano Cardé, Jin Niu, Yue Guo, et al.Advances in Therapy|March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple MyelomaPhilippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.Science Translational Medicine|March 22, 2013
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemiaRenier J Brentjens, Marco L Davila, Isabelle Riviere, et al.The Oncologist|March 11, 2020
Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar CarcinomaGhassan K Abou-Alfa, Robert Mayer, Alan P Venook, et al.Cancer Research|June 4, 2016
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome InhibitorsNeerav Shukla, Romel Somwar, Roger S Smith, et al.Future Oncology (London, England)|May 3, 2023
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myelomaPhilippe Moreau, Niels Wcj van de Donk, Hareth Nahi, et al.Pageof 24